Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Dose of GenSci098 in Patients With Graves' Disease

Next Previous
Trial Profile

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Dose of GenSci098 in Patients With Graves' Disease

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YB 101 (Primary)
  • Indications Goitre; Graves' disease
  • Focus Adverse reactions
  • Sponsors Changchun Jinsai Pharmaceutical

Most Recent Events

  • 27 Jul 2026 According to a Yarrow Bioscience media release, Yarrow Bioscience has merged with VYNE Therapeutics to form Yarrow Bioscience.
  • 17 Feb 2026 Planned End Date changed from 19 Feb 2027 to 18 Mar 2027.
  • 17 Feb 2026 Planned primary completion date changed from 19 Nov 2026 to 28 Oct 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top